Junctional adhesion molecule-A is dispensable for myeloid cell recruitment and diversification in the tumor microenvironment

oleh: Máté Kiss, Máté Kiss, Máté Kiss, Els Lebegge, Els Lebegge, Aleksandar Murgaski, Aleksandar Murgaski, Aleksandar Murgaski, Helena Van Damme, Helena Van Damme, Daliya Kancheva, Daliya Kancheva, Daliya Kancheva, Jan Brughmans, Jan Brughmans, Isabelle Scheyltjens, Isabelle Scheyltjens, Ali Talebi, Robin Maximilian Awad, Yvon Elkrim, Yvon Elkrim, Pauline M. R. Bardet, Pauline M. R. Bardet, Sana M. Arnouk, Sana M. Arnouk, Cleo Goyvaerts, Johan Swinnen, Frank Aboubakar Nana, Frank Aboubakar Nana, Jo A. Van Ginderachter, Jo A. Van Ginderachter, Damya Laoui, Damya Laoui

Format: Article
Diterbitkan: Frontiers Media S.A. 2022-12-01

Deskripsi

Junctional adhesion molecule-A (JAM-A), expressed on the surface of myeloid cells, is required for extravasation at sites of inflammation and may also modulate myeloid cell activation. Infiltration of myeloid cells is a common feature of tumors that drives disease progression, but the function of JAM-A in this phenomenon and its impact on tumor-infiltrating myeloid cells is little understood. Here we show that systemic cancer-associated inflammation in mice enhanced JAM-A expression selectively on circulating monocytes in an IL1β-dependent manner. Using myeloid-specific JAM-A-deficient mice, we found that JAM-A was dispensable for recruitment of monocytes and other myeloid cells to tumors, in contrast to its reported role in inflammation. Single-cell RNA sequencing revealed that loss of JAM-A did not influence the transcriptional reprogramming of myeloid cells in the tumor microenvironment. Overall, our results support the notion that cancer-associated inflammation can modulate the phenotype of circulating immune cells, and we demonstrate that tumors can bypass the requirement of JAM-A for myeloid cell recruitment and reprogramming.